Novo Ventures, the ventures arm of Novo Holdings, has published its review of the last 18 months, a period that saw significant progress across all areas of the business.
- $700 million invested in the life sciences
- $1 billion in exit proceeds
- 21 new portfolio companies added and 9 new portfolio company IPOs
- 6 company sales from the private company portfolio
- Expanded team with 3 promotions and 9 new additions, including 5 new partners
Novo Ventures is one of the largest international life science venture investors with a diversified portfolio of private and public biotech, medtech, and digital health investments in the US, Europe and Asia. The team has over 20 years of experience in investing in novel technologies, from early, translatable science through revenue-generating commercial opportunities.
Scott Beardsley, Managing Partner at Novo Ventures, said:
“Despite the volatile markets, Novo Ventures has been very active across the globe – adding over 20 portfolio companies and investing over $700 million. We also set a record for our group in terms of capital returned, with over $1 billion in exits including nine IPOs and six company sales from our private company portfolio.
During this period, we have also been busy strengthening the Novo Ventures team. We added five new Partners and several new Principals and Associates and now field a world-class team in San Francisco, Boston, London and Copenhagen.
Novo Ventures remains committed to its mission of investing in novel science and technology across the US, Europe and Asia in order to advance science and medicine for the benefit of society.”
For more information, please see Novo Ventures June 2022 Newsletter